“By officially grouping all ARSACS patients by age, sex, and especially geographic location, the foundation believes that large companies like Pfizer or Bayer will be more inclined to test new drugs.” . Article by Pierre-Alexandre Maltais, Journal de Québec ( French version only).
Interesting, right? Share with your friends & followers / Intéressant, non? Partagez avec vos amis: